{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:51:42Z","timestamp":1785282702237,"version":"3.55.0"},"reference-count":66,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Desmoid-type fibromatosis (DTF) is a locally invasive tumor composed of myofibroblast-like cells and collagen; it does not metastasize but can cause significant local morbidity. Most sporadic cases are associated with mutations in the CTNNB1 gene, which encodes beta-catenin. Various treatments have been used with differing efficacy and toxicity profiles. At our institution, pegylated liposomal doxorubicin (PLD) has become the preferred treatment for patients with DTF. We aim to describe our experience using PLD in patients with DTF who require treatment. Methods: A retrospective review of 61 DTF patients (41 females, 20 males) treated between 2000 and 2023 was conducted to assess the efficacy and toxicity of PLD. Results: Of the 26 patients treated with PLD, 23 had follow-up clinical data to assess benefit. Twenty-one showed clinical benefit, and only one progressed. Two patients did not benefit from PLD due to infusion reactions and chose alternative therapies. The primary side effect of PLD was hand-foot syndrome (HFS), but dose reduction and extended intervals allowed most patients to tolerate treatment. Other treatments, such as methotrexate, vinblastine\/vinorelbine, and sorafenib, also showed activity but had significant toxicities, including severe HFS, malaise, and hypertension. Interestingly, 31 out of 61 patients had a pre-existing history of psychiatric conditions (primarily depression and anxiety), and 6 of 41 women had personal or family history of polycystic ovary syndrome (PCOS). Additionally, 15 patients had obesity, and 4 had hypothyroidism. Conclusions: PLD is an effective and well-tolerated treatment for DTF, with good clinical responses at lower, tolerable doses. The association of pre-existing psychiatric diagnoses, PCOS, and obesity warrants further investigation.<\/jats:p>","DOI":"10.3390\/cancers17020293","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:27:58Z","timestamp":1737109678000},"page":"293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Benefit of Pegylated Liposomal Doxorubicin and High Prevalence of Pre-Existing Psychiatric Conditions in Patients with Desmoid-Type Fibromatosis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-0864","authenticated-orcid":false,"given":"Andrea","family":"Espejo Freire","sequence":"first","affiliation":[{"name":"Department of Medicine, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-9595","authenticated-orcid":false,"given":"Keith","family":"Skubitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mayocp.2017.02.012","article-title":"Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor","volume":"92","author":"Skubitz","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The Management of Desmoid Tumours: A Joint Global Consensus-Based Guideline Approach for Adult and Paediatric Patients","volume":"127","author":"Alman","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cam4.160","article-title":"Expression of FAP, ADAM12, WISP1, and SOX11 Is Heterogeneous in Aggressive Fibromatosis and Spatially Relates to the Histologic Features of Tumor Activity","volume":"3","author":"Misemer","year":"2014","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lee, Y.S., Joo, M.W., Shin, S.H., Hong, S., and Chung, Y.G. (2024). Current Treatment Concepts for Extra-Abdominal Desmoid-Type Fibromatosis: A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16020273"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rastrelli, M., Chiusole, B., Cavallin, F., Del Fiore, P., Angelini, A., Cerchiaro, M.C., Ruggieri, P., Sbaraglia, M., Mocellin, S., and Brunello, A. (2023). Desmoid Tumors in the Active Surveillance Era: Evaluation of Treatment Options and Pain Relief in a Single-Center Retrospective Analysis. J. Pers. Med., 13.","DOI":"10.3390\/jpm13121653"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1245\/s10434-013-3197-x","article-title":"Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought","volume":"20","author":"Bonvalot","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2014.11.019","article-title":"Sporadic Extra Abdominal Wall Desmoid-Type Fibromatosis: Surgical Resection Can Be Safely Limited to a Minority of Patients","volume":"51","author":"Colombo","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ejso.2016.02.012","article-title":"Extra-Abdominal Desmoid Fibromatosis: A Review of Management, Current Guidance and Unanswered Questions","volume":"42","author":"Eastley","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdt485","article-title":"Sporadic Desmoid-Type Fibromatosis: A Stepwise Approach to a Non-Metastasising Neoplasm-A Position Paper from the Italian and the French Sarcoma Group","volume":"25","author":"Gronchi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00776-007-1187-1","article-title":"Natural Course of Desmoid-Type Fibromatosis","volume":"13","author":"Nakayama","year":"2008","journal-title":"J. Orthop. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2010.33.5489","article-title":"Prognostic Factors Influencing Progression-Free Survival Determined from a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation","volume":"29","author":"Salas","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2106\/JBJS.M.00988","article-title":"Wait-and-See Policy as a First-Line Management for Extra-Abdominal Desmoid Tumors","volume":"96","author":"Briand","year":"2014","journal-title":"JBJS"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2006.08.2966","article-title":"Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II Trial","volume":"25","author":"Skapek","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y","article-title":"Low-Dose Chemotherapy with Methotrexate and Vinblastine for Patients with Advanced Aggressive Fibromatosis","volume":"92","author":"Azzarelli","year":"2001","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00000421-199904000-00020","article-title":"Therapy of Desmoid Tumors and Fibromatosis Using Vinorelbine","volume":"22","author":"Weiss","year":"1999","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/1097-0142(19890915)64:6<1192::AID-CNCR2820640605>3.0.CO;2-J","article-title":"Low-dose Chemotherapy of Desmoid Tumors","volume":"64","author":"Weiss","year":"1989","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.1999.17.3.1086","article-title":"Low-Dose Chemotherapy with Vinblastine and Methotrexate in Childhood Desmoid Tumors","volume":"17","author":"Reich","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","article-title":"Pegylated Liposomal Doxorubicin, an Effective, Well-Tolerated Treatment for Refractory Aggressive Fibromatosis","volume":"45","author":"Constantinidou","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2013","DOI":"10.1002\/ONCO.13516","article-title":"A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors","volume":"25","author":"Gennatas","year":"2020","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-20-1847","article-title":"Long-Term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status","volume":"26","author":"Mir","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1002\/1097-0142(19931201)72:11<3244::AID-CNCR2820721118>3.0.CO;2-D","article-title":"Combination Chemotherapy in Adult Desmoid Tumors","volume":"72","author":"Patel","year":"1993","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02053335","article-title":"Noncytotoxic Drug Therapy for Intra-Abdominal Desmoid Tumor in Patients with Familial Adenomatous Polyposis","volume":"35","author":"Tsukada","year":"1992","journal-title":"Dis. Colon Rectum"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/1097-0142(19871215)60:12<2863::AID-CNCR2820601202>3.0.CO;2-I","article-title":"The Use of Indomethacin, Sulindac, and Tamoxifen for the Treatment of Desmoid Tumors Associated with Familial Polyposis","volume":"60","author":"Klein","year":"1987","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/1097-0142(19920515)69:10<2478::AID-CNCR2820691016>3.0.CO;2-V","article-title":"Clinical and Cellular Effects of Colchicine in Fibromatosis","volume":"69","year":"1992","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1111\/cas.14626","article-title":"Desmoid with Biweekly Methotrexate and Vinblastine Shows Similar Effects to Weekly Administration: A Phase II Clinical Trial","volume":"111","author":"Nishida","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13577140310001644779","article-title":"Low Dose Methotrexate and Vinblastine, given Weekly to Patients with Desmoid Tumours, Is Associated with Major Toxicity","volume":"7","author":"Seynaeve","year":"2003","journal-title":"Sarcoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/cncr.11189","article-title":"Combination Chemotherapy for Desmoid Tumors","volume":"97","author":"Okuno","year":"2003","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/annonc\/mdr051","article-title":"Chemotherapy in Patients with Desmoid Tumors: A Study from the French Sarcoma Group (FSG)","volume":"23","author":"Garbay","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.25089","article-title":"Clinical Outcomes of Systemic Therapy for Patients with Deep Fibromatosis (Desmoid Tumor)","volume":"116","author":"Keohan","year":"2010","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2005.02.1923","article-title":"Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association with Familial Adenomatous Polyposis","volume":"24","author":"Gega","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02048164","article-title":"Use of Doxorubicin and Dacarbazine for the Management of Unresectable Intra-Abdominal Desmoid Tumors in Gardner\u2019s Syndrome","volume":"37","author":"Lynch","year":"1994","journal-title":"Dis. Colon Rectum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/BF02234783","article-title":"Extended Follow-up of Patients Treated with Cytotoxic Chemotherapy for Intra-Abdominal Desmoid Tumors","volume":"44","author":"Poritz","year":"2001","journal-title":"Dis. Colon Rectum"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jjco\/hyn004","article-title":"Dacarbazine-Doxorubicin Therapy Ameliorated an Extremely Aggressive Mesenteric Desmoid Tumor Associated with Familial Adenomatous Polyposis: Report of a Case","volume":"38","author":"Ezumi","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/cncr.11029","article-title":"Response of Extraabdominal Desmoid Tumors to Therapy with Imatinib Mesylate","volume":"95","author":"Mace","year":"2002","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1158\/1078-0432.CCR-10-1177","article-title":"Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial","volume":"16","author":"Chugh","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114119","DOI":"10.1016\/j.ejca.2024.114119","article-title":"Real-Word Experience of Pazopanib and Sorafenib in Patients with Desmoid Tumors: A CanSaRCC Multi-Center Study","volume":"205","author":"Noujaim","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41416-021-01320-1","article-title":"Rationale for the Use of Tyrosine Kinase Inhibitors in the Treatment of Paediatric Desmoid-Type Fibromatosis","volume":"124","author":"Orbach","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-009-1010-0","article-title":"Response of Imatinib-Resistant Extra-Abdominal Aggressive Fibromatosis to Sunitinib: Case Report and Review of the Literature on Response to Tyrosine Kinase Inhibitors","volume":"64","author":"Skubitz","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdq341","article-title":"Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC\/French Sarcoma Group Phase II Trial with a Long-Term Follow-Up","volume":"22","author":"Penel","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00432-007-0198-9","article-title":"Control of Aggressive Fibromatosis by Treatment with Imatinib Mesylate. A Case Report and Review of the Literature","volume":"133","author":"Wcislo","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-Secretase Inhibitor for Desmoid Tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mercatali, L., Vanni, S., Miserocchi, G., Liverani, C., Spadazzi, C., Cocchi, C., Calabrese, C., Gurrieri, L., Fausti, V., and Riva, N. (2022). The Emerging Role of Cancer Nanotechnology in the Panorama of Sarcoma. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.953555"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and Safety of Liposomal Anthracyclines in Phase I\/II Clinical Trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13569-018-0111-0","article-title":"Long-Term Cure of Soft Tissue Sarcoma with Pegylated-Liposomal Doxorubicin after Doxorubicin and Ifosfamide Failure","volume":"9","author":"Savani","year":"2019","journal-title":"Clin. Sarcoma Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00001813-199801000-00005","article-title":"Mechanism of Transient Dyspnea Induced by Pegylated-Liposomal Doxorubicin (DoxilTM)","volume":"9","author":"Skubitz","year":"1998","journal-title":"Anticancer Drugs"},{"key":"ref_47","first-page":"16","article-title":"Efficacy of Liposomal Doxorubicin in Patients with Intra-and Extra-Abdominal Desmoid Fibromatosis","volume":"40","author":"Dixon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11032","DOI":"10.1200\/JCO.2016.34.15_suppl.11032","article-title":"Pegylated Liposomal Doxorubicin (PLD) as an Active Treatment Option for Desmoid Tumor (DT) Patients","volume":"34","author":"Pang","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_49","first-page":"e53771","article-title":"Multifocal Desmoid-Type Fibromatosis: Case Series and Potential Relationship to Neuronal Spread","volume":"16","author":"Skubitz","year":"2024","journal-title":"Cureus"},{"key":"ref_50","first-page":"e28006","article-title":"Biclonal Desmoid-Type Fibromatosis with Two Beta-Catenin Mutations: Evidence for the Recruitment of Normal Myofibroblasts","volume":"14","author":"Skubitz","year":"2022","journal-title":"Cureus"},{"key":"ref_51","first-page":"e55496","article-title":"RAD51C and MYST3 Mutations in a Case of Desmoid-Type Fibromatosis with No Mutation in CTNNB1 or APC","volume":"16","author":"Skubitz","year":"2024","journal-title":"Cureus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","article-title":"Cardiac Safety Profile of Patients Receiving High Cumulative Doses of Pegylated-Liposomal Doxorubicin: Use of Left Ventricular Ejection Fraction Is of Unproven Value","volume":"80","author":"Skubitz","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac Safety Analysis of First-Line Chemotherapy Drug Pegylated Liposomal Doxorubicin in Ovarian Cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Ovarian. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0000000000000521","article-title":"Long-Term Use of Pegylated Liposomal Doxorubicin to a Cumulative Dose of 4600\u2009Mg\/M2 in Recurrent Ovarian Cancer","volume":"28","author":"Pendlebury","year":"2017","journal-title":"Anticancer Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ygyno.2013.03.012","article-title":"Continuing Routine Cardiac Surveillance in Long-Term Use of Pegylated Liposomal Doxorubicin: Is It Necessary?","volume":"129","author":"Gill","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ygyno.2015.02.020","article-title":"Selective Cardiac Surveillance in Patients with Gynecologic Cancer Undergoing Treatment with Pegylated Liposomal Doxorubicin (PLD)","volume":"137","author":"Kushnir","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1002\/pbc.26375","article-title":"Liposomal Doxorubicin: Effective Treatment for Pediatric Desmoid Fibromatosis","volume":"64","author":"Ananth","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_59","first-page":"552","article-title":"Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin","volume":"27","author":"Wehl","year":"2004","journal-title":"Onkologie"},{"key":"ref_60","first-page":"16","article-title":"Sorafenib Treatment Duration in Desmoid Tumors","volume":"42","author":"Yi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or Methotrexate\u2013Vinblastine Combination Chemotherapy in Adult Patients with Progressive Desmoid Tumours (DESMOPAZ): A Non-Comparative, Randomised, Open-Label, Multicentre, Phase 2 Study","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1158\/1078-0432.CCR-21-4504","article-title":"Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-Institutional Retrospective Study","volume":"28","author":"Nathenson","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.2848","article-title":"Lineage Tracing and Genetic Ablation of ADAM12+ Perivascular Cells Identify a Major Source of Profibrotic Cells during Acute Tissue Injury","volume":"18","author":"Dulauroy","year":"2012","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/2767-9764.CRC-22-0403","article-title":"CD142 Identifies Neoplastic Desmoid Tumor Cells, Uncovering Interactions Between Neoplastic and Stromal Cells That Drive Proliferation","volume":"3","author":"Xu","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pon.5250","article-title":"High Prevalence of Persistent Emotional Distress in Desmoid Tumor","volume":"29","author":"Ingley","year":"2020","journal-title":"Psychooncology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.cell.2024.08.050","article-title":"Brain-Body Physiology: Local, Reflex, and Central Communication","volume":"187","author":"Sammons","year":"2024","journal-title":"Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:49Z","timestamp":1759919449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020293"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020293","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}